Druck Icon

Eckert & Ziegler continue their upward trend in the third quarter of 1999

Eckert & Ziegler, specialists in the manufacture of low radioactive remedies for cancer and cardiac diseases, have continued their course of expansion in the third quarter. Profits increased by 480% to 7.0 million EUR in comparison with the previous year (1.2 million EUR). Cash flow rose from 0.3 million EUR to 2.5 million EUR and results from ordinary activities amounted to 0.7 million EUR during the period under review.

Profits generated by the sale of radioactive components for scientific and technological applications showed a particularly encouraging development in the third quarter. In comparison with the demand for oncological and cardiological products, although there was a high volume of orders here too, the increase was dramatic.

According to plan, the number of employees in the company was increased to 129 during the period under review. The Board of Directors expects a further significant increase as soon as the company moves into its new production and administrative buildings in Berlin-Buch in the spring of 2000. These buildings occupy an area of 2,100 sq m and will house numerous manufacturing lines for medical products marketed by various strategic partners in the cancer and cardiac field.

A detailed quarterly report is available by accessing our new company web-site (www.ezag.de) or can be requested directly from our company.

The Board of Directors